

# The European Restless Legs Syndrome Study Group

presents the

# First European Course on Diagnosis and Management of Restless Legs Syndrome

## Saturday, 15th December 2018

8:45 - 18:00

Auditorium "Pavillon", Klinikum Rechts der Isar, Ismaninger Str. 22, 81675 Munich, Germany

## National applications will be made for CME accreditation of this event

A world-renowned faculty will present the most up-to-date and relevant data on RLS and extensive opportunities will be offered to the audience to interact with these RLS experts

Official language: English

The European Restless Legs Syndrome Study Group (EURLSSG) is a non-profit association of RLS experts who are actively involved in RLS research and dedicated to optimising patient outcomes by continuously improving standards for diagnosis and treatment of RLS.

Intended audience: Healthcare professionals who encounter RLS patients in their clinical practice, including general practitioners, neurologists, and psychiatrists.

PROGRAMME Morning Session

8:45-11:30

20	Chairpersons: Yves Dauvilliers and Mauro Manconi O-minute lectures followed by 10 minutes discussion with the audience
08:45	Welcome and introduction Birgit Högl (EURLSSG President), Innsbruck, Austria
09:00	Diagnostic clues to RLS Birgit Högl (EURLSSG President), Innsbruck, Austria
09:30	RLS pathophysiology and genetics in a nutshell Barbara Schormair, Munich, Germany
10:00	RLS mimics and differential diagnosis Birgit Högl (EURLSSG President), Innsbruck, Austria
10:30	Which laboratory and other exams do I need to diagnose RLS? Diego Garcia-Borreguero, Madrid, Spain
11:00	RLS and comorbidity why is it no longer symptomatic RLS? Klaus Berger, Muenster, Germany
11:30	<b>The patient's perspective</b> Joke Jaarsma & Diego Garcia Borreguero



#### Interactive Lunch Session: An opportunity for participants to discuss difficult cases with an expert 12:00-13:00

First Afternoon Session: Treating RLS 13:00-15:30

Chairpersons:	Diego	Garcia-Borreguero	and Klaus Berger
	Diego	Guiola Dollogacio	

- 13:00What is augmentation, and how do you recognize it in time?Mauro Manconi, Lugano, Switzerland
- 13:20Are dopaminergic agents are still first line? How should they be used?<br/>Yves Dauvilliers, Montpellier, France
- 13:40 What is the role of alpha-2-delta ligands? When should they be initiated? Diego Garcia-Borreguero, Madrid, Spain
- 14:00 Discussion: Moderator Mauro Manconi

Each of the following 20-minute lectures is followed by 10 minutes discussion with the audience

- 14:30Opioids in RLS: when and how?Roselyne Rijsman, The Hague, The Netherlands
- 15:00 Iron for all RLS? What is the role of oral and intravenous iron? Rosalia Silvestri, Messina, Italy
- 15:15 **Dealing with augmentation** Diego Garcia-Borreguero, Madrid, Spain

#### 15:45-16:15 Coffee Break and networking

### 16:15-18:00: Second Afternoon Session: Treatment Issues in comorbid RLS

#### Chairpersons: Roselyne Rijsman and Barbara Schormair

Short, 12-minute patient-based interactive lectures followed by discussion with the audience at the end of the session

- 16:15 **RLS in pregnancy** *Mauro Manconi, Lugano, Switzerland*
- 16:27 **RLS in children** *Rosalia Silvestri, Messina, Italy*



16:39	RLS in depression Rosalia Silvestri, Messina, Italy
16:51	<b>RLS in Parkinson's disease</b> Roselyne Rijsman, The Hague, The Netherlands
17:03	RLS in end-stage renal disease (ESRD) Georgios Hadjigeorgiou, Larissa, Greece
17:15	<b>Cardiovascular / RLS in multi-morbid patients</b> Yves Dauvilliers, Montpellier, France
17:27	ICD risk in RLS: How should patients be informed, and how do you recognize and prevent it? Yves Dauvilliers, Montpellier, France
17:39	<b>Q&amp;A Session and closing remarks</b> Birgit Högl (EURLSSG President), Innsbruck, Austria
18:00	Close